Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis
After Phase II results fell slightly short of statistical significance, the company said it will test only a higher dose of the drug in Phase III trials and enroll patients with more severe psychosis.
Scrip - September 24, 2026

Lilly Joins Novo On Weekly Basal Insulin Market With FDA Nod
Lilly said Onswik can provide a convenience benefit for type 2 diabetes patients by reducing administration by 300+ doses per year, but Novo has a six-month lead in the US with Awiqli.
Scrip - September 24, 2026

The Race To The First Psychedelic Drug Approval Is On
Compass intends to complete the NDA for its synthesized psilocybin in Q4, setting it up to be the first true psychedelic on the market. Other companies are taking advantage of a more encouraging regulatory environment for psychedelic drug development.
Scrip - September 24, 2026

Due Diligence: Is Big Pharma Interest In Psychedelic Medicine Blooming?
What might Lilly’s buyout of AtaiBeckley, Otsuka’s acquisition of Transcend and the possible near-term approval of Compass Pathway’s psilocybin product portend for dealmaking in the psychedelic medicine space?
Scrip - September 24, 2026

Alexion Aims To Enter Crowded gMG Space With Convenience Advantage For Gefurulimab
AstraZeneca’s rare disease division plans to present 52-week data at a medical meeting next week and is awaiting an FDA decision on the drug, which already secured Japanese approval and a positive EMA CHMP decision.
Scrip - September 24, 2026

Merck’s Wnt Agonist Is Efficacious As New Mechanism For Eye Disease
Remigromig showed non-inferiority to Lucentis in a Phase IIb/III trial in diabetic macular edema, but with higher rates of safety issues.
Scrip - September 24, 2026

Publisher’s Spotlight: Scrip Awards Announces 2026 Finalists
We are delighted to announce the shortlist for the Annual Scrip Awards. Now in their 22nd year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health.
Scrip - September 24, 2026

Lilly Adds Another China Partner With InnoCare $100m Upfront Deal
The pharma giant continues its China partnering spree with a deal to discover and develop up to five therapies in cancer and autoimmune diseases.
Scrip - September 24, 2026

Kasvu All Set To Advance New Class In Depression
The Finnish biotech has banked €30m to take its non-hallucinogenic TrkB potentiator into the clinic.
Scrip - September 24, 2026

Simcere Envisions World-Facing R&D To Scale Up Global Partnerships
Simcere president Yunshu Zhou pinpoints Chinese firm’s next steps in deal making, based on a renewed R&D rationale in a global context.
Scrip - September 24, 2026

Precision Neuroscience Raises $250M In Series D To Advance Brain-Computer Interface
New York-based Precision Neuroscience closed an oversubscribed Series D financing round of $250m, led by Pershing Square and the Ackman Oxman Institute, which was founded by billionaire investor Bill Ackman. The money will be used to advance Precision’s investigational brain-computer interface.
Medtech Insight - September 24, 2026

Reboot Risk From React Health VOCSN Ventilators Prompts FDA Early Alert
The US FDA has issued an early alert concerning a potential issue with certain React Health VOCSN ventilators that can cause reboots and System Fault 10 alarms due to a loose internal flow transducer cable connector. No serious injuries or deaths have been reported.
Medtech Insight - September 24, 2026

New EU Regulation Addresses Many, But Not All, Of Medtech’s Procurement Concerns
MedTech Europe welcomes plans for value-based procurement, but argues that more definitive rules are needed.
Medtech Insight - September 24, 2026

Execs On The Move: September 14–18, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - September 24, 2026

FDA Panel Backs GRAIL’s Multi-Cancer Test, But Split Votes Put ‘Early Detection’ Claim In Play
The panel voted unanimously on safety but split 6-4 on effectiveness, and urged the agency to rein in “early” claims – a labeling fight that could set the bar for rival MCEDs and shape Medicare coverage from 2028.
Medtech Insight - September 24, 2026

CHPA RSQ Conference: From AI To UV Filters, NAMs To Supply Chain Security
Presentations at Sept. 28-30 conference include leaders from FDA’s drug and medical device centers and supplement program outlining priorities and projects and workshop on new approach methods for drug studies.
HBW Insight - September 25, 2026

Lipo Flavonoid Fails To Support Earwax Removal Efficacy, Safety And Market Claims In NAD Review
NAD says Lipo fails to support express claims for Earwax Cleansing Kit & Aid Drops including “5 times faster than traditional cleansers” and “clinically tested formula” challenged by eosera.
HBW Insight - September 25, 2026

Formycon Points To Benefits For Early Movers On Biosimilar Streamlining
Formycon has set out its belief that an early decision to terminate Phase III trials for its FYB206 proposed biosimilar to Keytruda (pembrolizumab) has played a “pioneering” role in demonstrating the benefits to developers of regulatory streamlining.
Generics Bulletin - September 24, 2026

Novartis Wins Entresto Antitrust Fight Over Six-Month Generic Delay
A New York federal court has dismissed an Entresto antitrust suit, finding Novartis properly listed the disputed ’659 patent in the Orange Book despite arguments that it did not specifically claim the drug’s valsartan-sacubitril complex.
Generics Bulletin - September 24, 2026

‘We Will Remain Relentless In Our Focus’ – Sandoz CCO Guntern On The Firm’s ‘Pure Play’ Ambitions
Speaking to Generics Bulletin after Sandoz unveiled its Bio 100 long-term strategy, chief commercial officer Rebecca Guntern discusses the significance of both small-molecule generics and biosimilars for the company, while also touching on aspects such as GLP-1s, US tariffs and M&A opportunities.
Generics Bulletin - September 24, 2026

Ondine’s Steriwave: Will New Antimicrobial Development Finally Be Rewarded With Commercial Success?
Ondine Biomedical has now published phase III topline data for Steriwave, its drug-device hybrid technology capable of vastly reducing rates of surgical site infections.
In Vivo - September 24, 2026